ABVACC, INC.

Rockville, MD · Biotech · Private

Monoclonal antibody cocktail (MR186-YTEAF and R217-YTE) for Marburg virus treatment

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Headquarters: Rockville, MD
Total capital: $10.9M

Federal grants: $7.4M; 11 awards · 2023–2026; Rank in peer group#85 of 514
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: $3.5M; 1 award · Health and Human S; Rank in Biotech#102 of 4373
Granted patents: 1; first 2023; Rank in peer group#186 of 514

Capital timeline

Latest events

May 2026Federal grantHealth and Human S · Phase II · Monoclonal Antibody Cocktail for Treatment of Marburg Virus Disease$1M
May 2025Federal grantHealth and Human S · Phase II · Monoclonal Antibody Cocktail for Treatment of Marburg Virus Disease$1M
Apr 2025Federal grantHealth and Human S · Phase II · Prophylactic Immunotherapy for Marburg Virus Disease Outbreak Control$915K
Jan 2025Federal grantHealth and Human S · Phase I · Development of a Marburgvirus subunit vaccineadjuvanted with a novel TLR7/TLR8 agonist$297K
Apr 2024Federal grantHealth and Human S · Phase II · Prophylactic Immunotherapy for Marburg Virus Disease Outbreak Control$918K
Feb 2024Federal grantHealth and Human S · Phase I · Development of a Marburgvirus subunit vaccineadjuvanted with a novel TLR7/TLR8 agonist$300K
Aug 2023Federal grantHealth and Human S · Phase I · Monoclonal Antibody Cocktail for Treatment of Marburg Virus Disease$293K

Show 5 earlier federal awards

May 2023Federal grantHealth and Human S · Phase II · Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis$315K
May 2023Federal grantHealth and Human S · Phase II · Prophylactic Immunotherapy for Marburg Virus Disease Outbreak Control$986K
Apr 2023Federal grantHealth and Human S · Phase II · Development of a Universal Immunotherapeutic for Influenza Viruses$380K
Apr 2023Federal grantHealth and Human S · Phase II · Immunotherapy of MRSA Osteomyelitis$1M
May 2021Federal contractHealth and Human S · To Develop A Potent Therapeutic Marburgvirus Monoclonal Antibody.$3.5M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#85 · top 17%
Granted patents#186 · top 36%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 1 granted of 1

Nov 28, 2023GrantedImmunogenic Composition Comprising A Fusion Peptide Derived From Superantigen ToxoidsUSPTOUS 11,826,412

ANTAGEN BIOSCIENCES INCSimilar federal contract value in Biotech · $3.7M in contracts
Proniras CorpSimilar federal contract value in Biotech · $3.7M in contracts
Helix, Inc.Similar federal contract value in Biotech · $3.6M in contracts
DNASTAR, INC.Similar federal contract value in Biotech · $3.4M in contracts
NOVOMEDIX LLCSimilar federal contract value in Biotech · $3.3M in contracts
SynthegoSimilar federal contract value in Biotech · $3.2M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.